At its April 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave ...

Mukhopadhyay took Mounjaro, an antidiabetic medication also used for weight loss, and saw dramatic results—losing 15 percent ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal” or the "Company”), an American biopharmaceutical company, and Apiject ...

Parenting coach, Wendy Ologe who wrote on “The Dark Side of Nigeria’s Egg Harvesting Industry: A Silent Exploitation of Young ...

While HHS Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil — a vaccine proven to prevent ...

Our proprietary system currently recommends Penumbra (PEN) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research shows that stocks ...

PEN boasts a Growth Style Score of A and VGM Score of B, and holds a Zacks Rank #2 (Buy) rating. Its bottom-line is projected to rise 69.4% year-over-year for 2025, while Wall Street anticipates ...

The most common treatment to correct low growth hormone levels is injections with synthetic growth hormone to correct the deficiency. These injections are often administered daily in children.

Scientists have now learned more about a process in which the genome of HPV links to human genes in cancer cells of oropharyngeal tumors; this leads to the formation of extrachromosomal circular DNA ...

More information: Takuya Nakagawa et al, Inhibition of human-HPV hybrid ecDNA enhancers reduces oncogene expression and tumor growth in oropharyngeal cancer, Nature Communications (2025).

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.